Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
To evaluate whether the proportion of patients who achieve cEVR (by Limit of Quantitation, LOQ, i.e. HCV RNA < 25 IU/mL) after 12 weeks of triple therapy with DEB025 600 mg/day combined with peg-IFNα2a 180 μg 1x/week and RBV 1000/1200 mg/day is higher compared to the proportion of patients who achieve cEVR after 12 weeks of placebo matching DEB025 treatment plus SOC therapy consisting of peg-IFNα2a 180 μg 1x/week + RBV 1000/1200 mg/day in chronic hepatitis C GT1 patients with previous non-response to SOC.
Critère d'inclusion
- Chronic hepatitis C